EZH2 and Hepatic failure: Because of the predominant nuclear localization of EZH2, and the small percentage of HSCs in liver tissues, specific EZH2 staining of activated HSCs in human samples has been difficult, however, increased global expression of EZH2 has been shown in mice treated with CCL4 vs controls,24 and in patients with liver failure and liver cancer as compared with healthy controls.33, 34